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the mechanisms of NSCLC progression and metastasis for targeting the drivers of lung cancer.
The human forkhead box (FOX) family comprises a group of evolutionarily conserved transcription factors which are characterized by a distinct DNA-binding forkhead domain. 5 FOXC1 (Mf1, FKHL7, FREAC3), a member of the FOX family, plays an important role in brain, 6,7 eye 8, 9 and heart formation 10, 11 during embryonic development. Recent studies have demonstrated that FOXC1 is substantially elevated in several aggressive human carcinomas, including basal-like breast cancer, [12] [13] [14] pancreatic ductal adenocarcinoma, 15, 16 gastric cancer, 17 hepatocellular carcinoma 18, 19 and acute myeloid leukemia, 20 and it is postulated to be a marker of poor prognosis.
Several previous studies have reported that FOXC1 is involved in multiple steps of tumor progression in breast cancer, including cell proliferation, migration, invasion, and epithelial to mesenchymal transition (EMT). [21] [22] [23] [24] [25] Few studies have focused on FOXC1 function in NSCLC. The precise mechanism of FOXC1 in regulating NSCLC progression remains unknown.
Lysyl oxidase is a copper-dependent enzyme involved in posttranslational cross-linking of both collagen and elastin, which, in turn, stabilizes the extracellular matrix (ECM), allowing for tissue maintenance and structural homeostasis. 26, 27 Accumulating data have indicated that LOX can create a stiffer microenvironment for tumor metastasis 28, 29 and induce pre-metastatic niche formation. 30, 31 It is associated with poor progression in various types of tumors, including non-small cell lung cancer [32] [33] [34] and is regarded as a targetable cancer metastasis molecule. 35 In our preliminary work, when FOXC1 was overexpressed, we identified 15 dramatic enrichment ECM-related genes by gene DNA microarray, among which LOX was especially upregulated (52-fold) .
In this study, we first identified FOXC1 as an important prognostic factor in NSCLC and showed clear biological implications in invasion and metastasis. We showed a correlation between FOXC1 expression and LOX expression and implicated LOX activity in the metastatic phenotype. Furthermore, we explored for the first time the mechanism of FOXC1 by directly binding in the promoter of LOX.
Finally, we showed that genetic silencing or pharmacologic inhibition of LOX can decrease metastasis in vitro and in vivo. This offers a new mechanistic insight into FOXC1 regulation in the invasion and metastasis of NSCLC and implicates FOXC1 as a potential therapeutic strategy for the treatment of NSCLC metastasis. The patients who had received neoadjuvant chemotherapy or radiotherapy before surgery were excluded. In addition, 40 biopsies from benign disease patients were used as control. Patients were contacted by phone to check on their health status and the last censor date was on 30 December 2017. Informed written consent was obtained from the patients who participated in the study and the study was approved by the hospital's institutional review board.
| MATERIAL S AND ME THODS

| Patients and samples
| Immunohistochemical staining
Immunohistochemistry (IHC) was performed as described previously. 36 Anti-FOXC1 pAb (1:100; Abcam) or anti-LOX mAb (1:300;
Abcam) was used in the IHC. Normal mouse or rabbit IgG instead of primary antibodies were used as negative control.
Immunohistochemical analysis was performed by two independent pathologists. The proportion score represented the estimated fraction of positive staining tumor cells (0 = none; 1 = less than 25%; 2 = 25%-75%; 3 = greater than 75%). The intensity score represented the average staining intensity of positive tumor cells (0 = none; 1 = week; 2 = intermediate; 3 = strong). The two scores were multiplied to generate the immunoreactivity score (IS) for each case (range = 0-9). FOXC1 expression was defined as either high expression (score ≥ 3) or low expression (score < 3).
| Cell culture
Human NSCLC cell lines A549, H226, H1975, H1650 and H1299 and normal pulmonary epithelial cell line BEAS-2B were purchased from the Cell Resource Center of the Chinese Academy of Sciences. H226, H1299, H1650 and H1975 cells were cultured in RPMI 1640 medium (Gibco, Life Technologies) with 10% FBS (Gibco, Life Technologies); A549 and BEAS-2B cells were cultured in DMEM (Gibco, Life Technologies) with 10% FBS. All cell lines were cultured at 37°C in a humidified atmosphere of 5% CO₂ incubator.
| Cell transfection
Lentiviral particles expressing FOXC1 were built by Genechem.
Briefly, H1299/H1650 cells were cultured in 6-well plates for 24 h; 500 µL fresh medium containing 10 µL lentivirus (1 × 10⁹ TU/mL) was then added to each well. After 12 h, the medium was refreshed and the infection rate was observed using a fluorescence microscope 72 h later. The stable cell lines were selected by puromycin (Invitrogen) and collected for later assays (after 4 weeks). The MOCK was a negative control. FOXC1 expression was detected by quantitative RT-PCR (qRT-PCR) and western blot.
Plasmid shFOXC1 (Genepharma) was transfected into the cells using X-treme GENE HP Reagents (Roche) according to the manufacturer's instructions; non-targeting plasmid (shNC) was used as a negative control. A549/H226 cells (2 × 10 5 ) were transfected with 2.5 µg plasmid in 6-well plates. The medium was refreshed after 12 h and the cells were collected 48 h later. After observing the infection rate using a fluorescence microscope 72 h later, the stable cell lines were selected by puromycin and collected for later assays after 4-6 weeks. FOXC1 expression was detected by qRT-PCR and western blot. The shRNA sequences are listed as follows:
shFOXC1-1:5′-GGGAATAGTAGCTGTCAAATG-3′; shFOXC1-2:5′-GGAGCTTTCGTCTACGACTGT-3′;
shNC: 5′-GTTCTCCGAACGTGTCACGT-3′.
To silence LOX expression, siRNA against human LOX (Genepharma) was transfected into NSCLC cells. The siRNA sequences are listed in Table S1 .
| Western blot assay
Total proteins were loaded on a 10% SDS-PAGE gel and transferred onto a polyvinylidene difluoride membrane (Millipore).
Subsequently, the membrane was blocked by TBST containing 5% non-fat milk for 1 hour and incubated overnight at 4°C with the primary antibodies against FOXC1 (1:1000; Abcam), LOX (1:1000; Abcam) and anti-GAPDH mAb (1:5000; Proteintech) as an internal control. Afterwards, the blots were labeled for 1 h with HRP-conjugated secondary antibody (1:10 000; Proteintech). Finally, the blots were exposed to the ChemiDoc XRS + system (Bio-Rad).
| Quantitative RT-PCR assay
Total RNA was extracted from NSCLC cells using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. cDNAs were synthesized from total RNA (2 µg) using the PrimeScript RT Reagent Kit with gDNA eraser (Perfect Real Time) (TaKaRa).
QRT-PCR was carried out with an ABI7500 sequence detector (Applied Biosystems) using SYBR Premix Ex Taq Ⅱ (Tli RNaseH Plus) (TaKaRa). The forward and reverse primer sequences are listed in Table S2 . Gene expression was determined by the 2 −ΔΔCt method using GAPDH as an internal control. All experiments were repeated at least three times.
| Cell proliferation assay in vitro
Cell proliferation was assessed with the Cell Counting Kit-8 (CCK8) assay. Cells were seeded in 96-well plates at 1 × 10 3 cells per well, then treated with 100 µL medium without FBS and 10 µL CCK8 solution and incubated for 2 h at 37°C. The Microplate Absorbance Reader was used to read the absorbance at 450 nm at 24, 48, 72, 96 and 120 h, respectively. Assays were repeated at least three times.
| Colony formation assay in vitro
Cells were plated in 6-well plates at a starting number of 2 × 10 2 cells. Cell colonies were stained with Giemsa (Solarbio) and counted after 2-3 weeks of culture. Each experiment was performed at least three times.
| Wound-healing assay
Cells were seeded at a density of 1 × 10 5 cells/mL in 6-well plates.
A scratch wound was created across the center of the monolayer of cells in each well with a sterile 200-µL pipette tip. Images of the cells that had migrated into the cell-free scratch wound area were acquired and the migration area was measured under an inverted microscope. The scratch wound area was determined by the relative percentage compared to untreated control cells. Assays were repeated at least three times. 
| Cell migration and invasion assays in vitro
| Whole genome DNA microarray
Cells transfected with FOXC1 and negative control were collected using TRIzol Reagent (Invitrogen, Life Technologies) according to protocol. Then, the samples were amplified and labeled using the RNeasy Mini Kit (Qiagen p/n 74 104). Next, the samples were hybridized using the Agilent Gene Expression Hybridization Kit (Agilent Technologies) in Agilent SureHyb hybridization chambers.
After hybridization and washing, the slides were scanned with the Agilent DNA microarray scanner using the settings recommended of Agilent Scan Control software. The data were collected using the Agilent Feature Extraction Software (version 11.0.1.1) and analyzed using GeneSpring GX software (version 11.5.1).
| Bioinformatics prediction tools
The transcription factor targeted gene was analyzed by using the online database and tools in the Eukaryotic Promoter Database 
| Luciferase reporter assay
The pGL4.10-Lox promoter (wild-type or mutant) was cloned. Cells were cultured in 24-well plates and co-transfected with pGL4.10-Lox promoter or pGL4.10-Lox promoter mutant vectors (200 ng) and mimics (100 ng) of the FOXC1 plasmid using Lipofectamine 2000.
Luciferase activity was measured 24 h later with a Dual-Luciferase
Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity, and the effect of FOXC1 on luciferase reporter with LOX promoter region was then normalized with that on luciferase reporter without LOX promoter region.
| ChIP assay
ChIP assays were performed as described in the protocol with modifications. 37 FOXC1 antibody was used for the CHIP assay to recognize endogenous FOXC1 (1:1000; Abcam). IgG was the negative control. A 127-bp fragment in the LOX was amplified using standard PCR conditions. Primer sequences are described in Table S3 . The amplified fragments were analyzed in a 2% agarose gel. 
| Subcutaneous xenograft and tail vein-lung metastasis tumor models
Each group has 6 mice; 1 × 10⁶ cells (H1299-MOCK, H1299-FOXC1
or A549-shNC, A549-shFOXC1) were subcutaneously inoculated into the left axillary of each mouse. Seven days after tumor cell inoculation, each mouse was treated daily with or without l; 100 mg/kg; Sigma-Aldrich) for the last four weeks. BAPN were used to inhibit the LOX role. PBS was used as control. Tumor sizes were monitored every 3 days using calipers and tumor volumes were calculated according to the formula: length × width 2 × 0.5.
To observe the role of FOXC1 in distant metastasis, FOXC1
overexpressing or silencing cells and their corresponding controls were injected intravenously with 5 × 10 5 cells in 0.1 mL DMEM medium via tail vein. Seven days later, each mouse was treated daily with or without BAPN for the last four weeks. Mice were killed and visible lung surface micrometastatic white spots were counted using a dissecting microscope (Nikon) at 36 days.
Histological analyses were used to detect metastasis in lungs which were embedded in paraffin and dyed with H&E. Animal studies were conducted in accordance with the NIH animal use guidelines and current Chinese regulations and standards for laboratory animal use.
| Lysyl oxidase activity assay
The original fluorescence-based method was used to assess LOX enzymatic activity as described previously. 38, 39 For the in vivo assay, terminal blood was taken from mice at the end of the experiment 
| Statistical analysis
Statistical analysis was carried out with SPSS 15.0. Values are presented as the mean ± SEM. Statistical differences between groups were identified using Student's t test, ANOVA, χ 2 or Fisher's exact test, and Pearson's correlation test, as appropriate. Overall survival curves were calculated using the Kaplan-Meier method and significance was determined using the log-rank test. P < .05 was considered statistically significant. All the experiments were conducted in triplicate.
| RE SULTS
| Highly expressed forkhead box C1 in human non-small cell lung cancer correlated with poor prognosis
To determine FOXC1 expression in NSCLC, IHC was performed in 105 primary human NSCLC tissues and 40 adjacent nontumorous tissues. As presented in Figure 1A We further analyzed the association between FOXC1 expression and the clinicopathological parameters. As presented in Table 1 , the high expression of FOXC1 was observed more often in patients with positive lymph node status (N0, 37.8%; N1 + N2, 66.2%, P = .005) and in non-squamous NSCLC patients (squamous NSCLC, 42.6%; non-squamous NSCLC, 67.2%; P = .011). Its expression was higher in stage II + III (61.8%) but did not approach significance (P = .059). No statistically significant correlations were identified between FOXC1 expression and gender, age, smoking history, differentiation or tumor size. More importantly, patients with high expression of FOXC1 showed poorer overall survival than those with low expression (P = .0472) ( Figure 1C ). Table 2 ). The result indicated that FOXC1 high expression was negatively correlated with patient survival.
| Forkhead box C1 promoted proliferation, migration and invasion of non-small cell lung cancer cells in vitro
To investigate the role of FOXC1 in NSCLC progression, we first determined FOXC1 expression in five NSCLC cell lines (A549, H226, H1975, H1650 and H1299) and the normal lung/bronchial epithelial cell line (BEAS-2B). We found that FOXC1 expression was significantly higher in five NSCLC cell lines compared with that in BEAS-2B ( Figure S1 ). Then, we selected H1299 and H1650 with endogenous low FOXC1 expression to be constructed two (Figure 2A more quickly than control cells (Figure 2G ,H) and significantly promoted the migration and invasion of lung cancer cells ( Figure 2I to L).
Meanwhile, we also selected A549 and H226 with endogenous Taken together, these findings suggested that FOXC1 can promote proliferation, migration and invasion of NSCLC cells in vitro.
| Forkhead box C1 overexpression promoted non-small cell lung cancer progression in vivo
To assess the contribution of 
| Lysyl oxidase was a downstream target of forkhead box C1
To define the mechanism of FOXC1 promoting tumor progression, we examined transcriptome changes mediated by FOXC1 overexpression in H1299 cells on gene expression profiles. Gene Ontology analysis revealed that several biological processes were altered ( Figure 5A ). Metastasis is a complicated multistep that involves Hence, we focused on several ECM-related genes, including FN1, MMP7, MMP1, LOX, COL1A1, ITGA2, ANK3, IGFBP3 and CD24 when FOXC1 overexpression changed (Table S4) . Among these genes, we focused on LOX, which were strongly upregulated by FOXC1 overexpression (Figure 5B ), and demonstrated that LOX protein was upregulated in invasive lung adenocarcinoma. 32 To further demonstrate the association between LOX and Overexpression of FOXC1 in H1299 and H1650 cells dramatically increased LOX mRNA and protein expression ( Figure 5C,D) , while the FOXC1-silenced cells provided the opposite results ( Figure 5E,F) .
To explore the molecular mechanism by which FOXC1 regulates LOX, online analysis of bioinformation revealed that the FOXC1 may combine in the LOX promoter. We examined the LOX promoter sequence and detected five putative FOXC1 binding sites in the LOX promoter ( Figure S2 ). Thereafter, luciferase reporter plasmids carrying the wild type (WT) or mutant LOX promoter regions were co-transfected with the Renilla luciferase reporter plasmid into H1299 cells. As the reporter assays showed, overexpression of FOXC1 and LOX-luc significantly enhanced the activity of luciferase reporters driven by LOX promoter compared with the three controls ( Figure 5G ). Consistent with this result, CHIP analysis further confirmed that FOXC1 could bind directly in the LOX promoter region in cells ( Figure 5H,5I ).
| Lysyl oxidase was essential for forkhead box C1-mediated non-small cell lung cancer invasion and metastasis
To determine whether the effects of FOXC1 in NSCLC metastasis are mediated by LOX, we first assessed the function of LOX in A549 and H226 cells transfected with LOX-siRNA ( Figure 6A ). The results showed that the cell proliferation was not significantly attenuated in siLOX-transfected A549 and H226 cells ( Figure S3A Figure 6F to H, Figure S3F to H). However, LOX downregulation in those cells had no significant effect on cell proliferation ( Figure S3E) . These results demonstrated that LOX was essential for FOXC1-mediated NSCLC invasion and metastasis but not proliferation in vitro.
In addition, to assess the role of LOX in FOXC1-mediated NSCLC progression in vivo, we also analyzed the tumor growth and metas- Figure   S4A to G). As for the in vivo assay, some mice were treated daily with 100 mg/kg BAPN as described for the last weeks and terminal bleeds were taken from mice at the end of the experiment. We observed that the LOX activity level in the blood of BAPN-treated mice was obviously reduced, which was confirmed in an in vitro assay ( Figure S4H ). All these results provided powerful evidence that LOX was essential for FOXC1mediated NSCLC invasion and metastasis in vitro as well as in vivo.
| Correlation between forkhead box C1 and lysyl oxidase expression in vivo
The positive correlation between FOXC1 and LOX in NSCLC cells reminded us to investigate whether such a relationship also exists in NSCLC patients and xenograft models. We first determined shown in Figure 7A . The data showed that LOX expression in the tumor was higher than in paratumor tissues (P < .01) ( Figure   S5A ). Furthermore, NSCLC patients with LOX high expression have shorter overall survival than patients without LOX expression ( Figure S5B , P = .0456). The upregulation of LOX was also positively correlated with the level of its master regulator FOXC1
( Figure 7B , P < .01, r = .6257). Finally, we found that positive coexpression of FOXC1/LOX predicted the lowest overall survival in NSCLC patients ( Figure 7C) . Similarly, the positive correlation between FOXC1 and LOX expression was also observed in subcutaneous xenograft models ( Figure S5C ). The specificity of FOXC1 and LOX antibodies have been verified ( Figure S6 ). Recent studies have demonstrated that FOXC1 is highly expressed in various cancers, [40] [41] [42] including NSCLC, 43 and is postulated to be a marker of poor prognosis 17, 18 In the present study, inhibited the proliferation and migration of A549 cells. 45 Taken together, these results indicated that FOXC1 was involved in tumorigenesis and progression of the NSCLC through promoting tumor cell growth and metastasis.
FOXC1 promoted metastasis and invasion through inducing
EMT, 25 increasing breast cancer stem cell properties, 46 and was in- and invasion. 48 However, the precise function and mechanism by which FOXC1 exerts its functions in NSCLC remains to be elucidated. Our study showed, for the first time, that FOXC1 promoted migration and invasion through directly targeted LOX expression in NSCLC.
LOX, a member of a five-member family of amine oxidases, has been shown to be an important regulator of the ECM. 49 Emerging evidence implicates LOX as being strongly associated with poor progression in various tumors, including non-small cell lung cancer, and it is regarded as a targetable secreted molecule involved in cancer metastasis. 26, 30, 32, 34, 50 Downregulation of LOX in H1650 and H1299 cells transfected with FOXC1 vector or inhibition of LOX activity using BAPN inhibited the FOXC1-driven effects on cell migration and invasion in vitro, and inhibition of LOX activity using BAPN decreased the number of lung metastases in vivo, which suggested that FOXC1-LOX axis was involved in the metastasis and invasion of NSCLC and FOXC1 promoted metastasis by regulating LOX expression. In this study, we also found that LOX knockdown failed to influence the proliferation in those cells. This conclusion is different from the findings of Kanapathipillai et al. 51 The reason might be that the modulation of other cellular pathways or proteins induced by FOXC1 compensated for the inhibition of cell growth mediated by LOX downregulation. However, the above conclusion is consistent with the results of Erler et al, who found that inhibition of LOX (with siRNA or BAPN) did not have a major effect on tumor growth, and there was no association between tumor size and the number of metastases. 28 After all, homeostasis is a complex regulated network. Weaver and colleagues demonstrated LOX-mediated collagen crosslinking as a contributor to tumor matrix stiffening, which led to enhanced integrin signaling and invasive behavior in tumors. 49, 52 Cox et al identified LOX as a novel regulator of the formation of focal premetastatic lesions, which provided a platform for circulating tumor cells to colonize and form bone metastases. 53 Tang et al found that LOX regulated the EGFR to drive tumor progression. 29 However, the exact downstream target of LOX and the signal pathway of the LOXinduced metastasis and invasion in NSCLC cells needs to be further characterized.
In summary, our study found a positive correlation between 
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